Doxorubicin Hydrochloride Injectable, Liposomal
Product Images NDC 72603-103

Not available.*

NDC 72603-103-01 is a liposomal formulation of DOXOrubicin Hydrochloride that is a Cytotoxic Agent and must be diluted. It is meant for intravenous infusion only after dilution. The drug must be diluted using 5% Dextrose Injection, USP. The drug is stored in a fridge with a temperature range of 2°C to 8°C (36°F to 46°F) but it must not be frozen. The drug comes in a 10 mL Single-Dose Vial and it should be retained in the carton until time of use. Any unused portion should be discarded. The manufacturer of the drug is Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Guijarat, India. The information about the usual dosage can be found in the prescribing information.*

This is a description of a drug called DOXOrubicin Hydrochloride Liposome Injection, which is a sterle cyotoxic agent. It needs to be diluted before administration and is only for intravenous infusion. The drug comes in a 50 mg/25 mL (2mg/ml) single-dose vial, and it has to be stored in a refrigerator. The manufacturer is Northstar Rx LLC, and the package code is NDC 72603-200-01. The composition of each ml of the drug contains doroni hydrochloride, USP 2mg along with other listed compounds. The formulation is liposomal, and the instructions specify not to substitute the drug. There are other details regarding dosage and storage of the drug.*

This text is a product label for Doxorubicin Hydrochloride Liposome Injection. The medication is a cytotoxic agent that must be diluted before use. The label provides instructions on how to properly dilute and store the medication. The medication comes in a 25 mL single-dose vial and should be diluted with 5% Dextrose Injection. The dosage information is provided in the prescribing information. The medication must be refrigerated and not frozen, and unused portions should be discarded. The manufacturer is Northstar Rx LLC, and it was manufactured in India. *

The text describes the representation of a pegylated liposome that consists of a liposomal bilayer with an aqueous core that has entrapped doxorubicin HCI, coated by MPEG-DSPE.*

This is a clinical trial that compared two treatments for cancer, Doxorubicin+Bortezomib and Bortezomib, in terms of survival rates. The trial involved 646 subjects who were followed up over a period of 14 to 67 months. The study found that patients who received Doxorubicin+Bortezomib had a statistically significant better survival rate than those who received Bortezomib alone (p-value < 0.0001). The hazard ratio (HR) (95% CI) was 0.55 (0.43, 0.71), indicating that the risk of death was 45% lower in the first group. The table shows the number of subjects at risk in each group at different time points.*

This appears to be a description of a structural formula for a compound, with some symbols and atoms connected by lines. The compound appears to be called "HSPC" and has a specific arrangement of carbon, hydrogen, nitrogen, and phosphorus atoms. The note about the molecular weight suggests that there may be two different versions of the compound with slightly different numbers of carbon and hydrogen atoms. Without more context, it is not possible to say what HSPC is used for or how it behaves.*